The evolution of SARS-CoV-2 seroprevalence in Canada: a time-series study, 2020-2023

The evolution of SARS-CoV-2 seroprevalence in Canada: a time-series study, 2020-2023

Interpretation: Data up to March 2023 indicate that most people in Canada had acquired antibodies against SARS-CoV-2 through natural infection and vaccination. However, given variations in population seropositivity by age and geography, the potential for waning antibody levels, and new variants that...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Canadian Medical Association journal (CMAJ) 2023-08, Vol.195 (31), p.E1030
Hauptverfasser: Murphy, Tanya J, Swail, Hanna, Jain, Jaspreet, Anderson, Maureen, Awadalla, Philip, Behl, Lesley, Brown, Patrick E, Charlton, Carmen L, Colwill, Karen, Drews, Steven J, Gingras, Anne-Claude, Hinshaw, Deena, Jha, Prabhat, Kanji, Jamil N, Kirsh, Victoria A, Lang, Amanda L.S, Langlois, Marc-Andre, Lee, Stephen, Lewin, Antoine, O'Brien, Sheila F, Pambrun, Chantale, Skead, Kimberly, Stephens, David A, Stein, Derek R, Tipples, Graham, Van Caeseele, Paul G, Evans, Timothy G, Oxlade, Olivia, Mazer, Bruce D, Buckeridge, David L
Format: Artikel
Sprache:eng
Schlagworte:
Canada
Epidemics
Risk factors
Statistics
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Interpretation: Data up to March 2023 indicate that most people in Canada had acquired antibodies against SARS-CoV-2 through natural infection and vaccination. However, given variations in population seropositivity by age and geography, the potential for waning antibody levels, and new variants that may escape immunity, public health policy and clinical decisions should be tailored to local patterns of population immunity.
ISSN:0820-3946
1488-2329
DOI:10.1503/cmaj.230949